Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06326216 · ClinicalTrials.gov registry record
Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer
A clinical trial of Prostate Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 98
- Enrollment target
- 1
- Study location
NCT06326216: Active study of Prostate Carcinoma, sponsored by Mayo Clinic.
NCT06326216 is a study of Prostate Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 98 participants, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06326216, a study of Prostate Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer.
Primary Outcome
Levels of prostate cancer-derived EVs will be assessed using blood and urine samples
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2020-06-10 |
| Est. Completion | 2026-12-01 |
What the registry record for NCT06326216 still lists
NCT06326216 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06326216 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06326216 about?
NCT06326216 is a clinical study titled "Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer". This study is being done to determine whether levels of prostate cancer derived extracellular vesicles from blood and urine specimens correlate with response to primary local treatment (surgery) in prostate cancer.
What is the current status of trial NCT06326216?
This trial is currently active not recruiting. The enrollment target is 98 participants. The study started on 2020-06-10. Estimated completion is 2026-12-01.
What conditions does trial NCT06326216 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT06326216?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06326216?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06326216 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06326216's enrollment target sits among peer trials
98 28th of 59 higher than 31 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
RECRUITING
-
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
RECRUITING · Phase 2
-
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
RECRUITING · Early Phase 1
-
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI